Measure activation of cell signaling pathways using MILLIPLEX® bead-based multiplex assays. Multiplexing with cell signaling phosphoprotein assays based on Luminex® xMAP® technology helps researchers measure multiple phosphoproteins or total proteins within the same pathway or different pathways from a single sample. Read on to see how this can advance research on cancer, immunology/inflammation, toxicity, and more.
Multiplexing provides faster answers to intracellular pathway questions compared to traditional Western blots, mass spectrometry, and radioactive phosphorylation assays that require large amounts of sample. For example, with MILLIPLEX® multiplex assays, based on Luminex® xMAP® technology, researchers get the gift of time and sample. Table 1 shows a comparison of MILLIPLEX® assays to Western blot assays.
MILLIPLEX® intracellular pathway multiplex kits and panels are analytically verified using the same stringent performance criteria used to manufacture our circulating biomarker kits, and they are optimized to yield maximum data from precious samples. Our cell signaling assays enable accurate relative quantitation of both total and phosphorylated forms of signaling proteins, revealing connections and crosstalk within your pathways of interest.
These analytically verified intracellular pathway assay kits offer:
Cell signaling multiplex assays help to compare phosphoprotein and total protein levels from a sample which gives insights into different signaling pathways including cancer, inflammation, and even the endocannabinoid system. Examples of intracellular pathways that are being analyzed with multiplex kits include:
Specifically, cell signaling assays are critical in cancer research due to the complex signaling pathways involved in cancer and metastasis. Below describes examples of how researchers are using MILLIPLEX® cell signaling multiplex assays in cancer research.
Bcl-2 family members play a very important role in intrinsic apoptotic pathways. The family consists of more than 17 members that can be functionally separated into pro-apoptotic and anti-apoptotic subfamilies. Interactions between these family members determine cell fate, and dysregulation can lead to tumor growth and tumor cell survival.
There are several investigational drugs for cancer treatment targeting Bcl-2 family members in clinical trials, driving the need for robust assays to measure Bcl-2 family members and their interactions. Though existing assays measure Bcl-2 family members, there is a lack of reliable assays to evaluate total proteins and protein-protein interactions simultaneously. To address this issue, two Luminex® technology-based multiplex immunoassay panels that allow for the simultaneous detection of multiple components of the Bcl-2 family in a single well, including Total Bcl-2, Bcl-xL, Mcl-1, BAD, BIM, and BAX, as well as protein interactions like Mcl-1/BIM, Bcl-xL/BAD, and NOXA/Mcl-1* (*data not shown) were developed.
Using the MILLIPLEX® Bcl-2 Family Apoptosis Panel 1 and Panel 2, changes in the expression and interactions of Bcl-2 family members were analyzed in response to known apoptotic drugs, including camptothecin (topoisomerase inhibitor), anisomycin (protein translation inhibitor), and AT101 (BH3 mimetic drug). Camptothecin and anisomycin each elicited a significant decrease in the levels of Mcl-1 as well as a slight decrease in BIM levels. Additionally, the Mcl-1/BIM interaction was disrupted by both camptothecin and anisomycin probably due to reduced levels of both the proteins.
AT101, on the other hand, had no significant effect on either Mcl-1 levels or the Mcl-1/BIM interaction. In contrast to their disparate effects on the Mcl-1/BIM interaction, all three drugs acted similarly in blocking the Bcl-xL/BAD interaction without affecting the total levels of either protein. Figures 1 and 2 show data from the drug dose-dependent study in the MCF7 cell line using the MILLIPLEX® Bcl-2 Family Apoptosis Panel 1 and Panel 2 respectively.
Figure 1.Drug dose-dependent analysis was completed using MILLIPLEX® Bcl-2 Family Apoptosis Panel 1. MCF7 cells were treated with 0, 1, 2, 5, 10, and 20 μM concentrations of camptothecin, anisomycin, and AT101 for 16 hours. 20 μg total protein of each lysate diluted in MILLIPLEX® Assay Buffer 1 was analyzed according to the assay protocol (lysate incubation at 4°C overnight).
Figure 2. Drug dose-dependent analysis was completed using MILLIPLEX® Bcl-2 Family Apoptosis Panel 2. MCF7 cells were treated with 0, 1, 2, 5, 10, and 20 μM concentrations of camptothecin, anisomycin, and AT101 for 16 hours. 20 μg total protein of each lysate diluted in MILLIPLEX® Assay Buffer 1 was analyzed according to the assay protocol (lysate incubation at 4°C overnight). Note, data is not shown for the NOXA/Mcl-1 protein interaction.
Overall, these results illustrate the dynamic responses of the Bcl-2 family to apoptosis-inducing drugs. The novel MILLIPLEX® multiplex immunoassays described here provide a powerful tool for studying the underlying mechanisms regulating the Bcl-2 family of proteins.
Ras proteins (HRAS, KRAS, and NRAS) are small GTPases that function as molecular switches by alternating between inactive GDP-bound and active GTP-bound states. Ras-GTP activates downstream pathways, including the MAPK pathway by binding to Raf kinase and phosphatidylinositol 3-kinase (PI3K) to promote cellular proliferation, survival, growth, and differentiation. Oncogenic mutations in Ras are found in approximately 25% of human cancers. Furthermore, 90% of pancreatic cancers harbor KRAS mutations with 80% of KRAS mutations occurring at codon 12 with Ras G12V and G12D being the most prevalent.
The Ras-Raf-MEK pathway can also be activated downstream of Ras. BRAF is a well-established oncogene, with the BRAF V600E mutation being prevalent in melanoma. While targeting this BRAF oncoprotein has had therapeutic efficacy, treating cancers driven by Ras oncoproteins remains an urgent unmet clinical need.
The MILLIPLEX® Ras-Raf Oncoprotein Magnetic Bead Panel was developed to simultaneously detect total Ras, Ras G12V, Ras G12D, phospho-MEK1 (S217/S221), phospho-BRAF (S446), and phospho-CRAF (S338) in a single well. This multiplex assay detects the H-Ras, N-Ras, and K-Ras isoforms for total Ras, RasG12D, and RasG12V. To confirm specific recognition of mutant Ras oncoproteins, this kit can detect the known KRAS G12V mutation found in the COR-L23 cell line and the NRAS G12D mutation found in the THP-1 cell line, respectively (Figure 3).
Figure 3. THP-1 cells and COR-L23 cells were treated with 2 μM vemurafenib or 125 nM dabrafenib for 72 hours before cells were harvested and cell lysates were analyzed using the MILLIPLEX® Ras-Raf Oncoprotein Panel. No effects of vemurafenib or dabrafenib were observed in these cell lines lacking BRAF mutation.
In addition, the response to the BRAF inhibitors, vemurafenib and dabrafenib, was compared between MDA-MB-435S cells, which harbor the BRAF V600E mutation, and insensitive cell lines, using multiplex immunoassays (Figure 4).
Further, commercially-sourced tissue lysates were analyzed using tumor and adjacent tissue from a patient with colon cancer harboring a KRAS G12D mutation. Finally, exosomes were enriched from pancreatic cancer serum and tested using the Ras-Raf Oncoprotein Panel (data not shown). This data demonstrates the utility of studying the effects of Ras oncoproteins by MILLIPLEX® multiplex immunoassays in multiple sample types, including cell, tissue, and exosomal lysates.
Below describes some tips and tricks on using our MILLIPLEX® singleplex and multiplex cell signaling assays.
We offer three kit formats of MILLIPLEX® cell signaling assays to meet your diverse research needs.
To continue reading please sign in or create an account.Don't Have An Account?